CINCINNATI and DURHAM, N.C., April 28, 2016 /PRNewswire/ -- Schulman IRB, the industry-leading central IRB in customer service and technology, is proud to be a platinum partner of the 2016 MAGI East Clinical Research Conference. The conference will be held from May 1-4 at the Westin Copley Place in Boston, Massachusetts.
"The MAGI East Conference is one of the most well-known conferences in the clinical research industry. We are looking forward to engaging in this year's sessions and workshops, as well as networking with some of the most respected professionals in our space," said Robann Cunningham, Vice President of Sales and Marketing at Schulman.
Three members of Schulman's team will speak at various sessions throughout the conference. Eli Alford, COO, will speak at a special topics track on practical negotiation techniques. Schulman's Institutional Official and Vice President of Compliance and Board Operations, Rebecca Ballard, will host "Human Subjects Protection Jeopardy." And Rebecca Rogers, IRB Chair, will discuss the complex challenges unique to oncology research.
In addition to these three speakers, Schulman will also be sponsoring the Zenith reception on Monday, May 2 from 5:30 PM-7:00 PM.
To learn more about the event, visit http://www.magiworld.org/events/2016E/.
About Schulman IRB
Schulman IRB has been a leader in the protection of human research participants in the U.S., Puerto Rico and Canada since 1983. Schulman offers thorough, timely IRB review services – including dedicated review capabilities for all phases of research across all therapeutic areas – to clinical trial sponsors, CROs, investigators and institutions. Schulman also provides global consulting services through its joint venture partner Provision Research Compliance Services, offering comprehensive solutions to maximize the protection of human subjects and improve overall quality standards for clinical studies and data integrity. Fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), Schulman has an unparalleled clean audit history with the Food and Drug Administration (FDA).
SOURCE Schulman IRB